Cited by 110Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsChemokine receptors and signaling

Rapid Transport of CCL11 across the Blood-Brain Barrier: Regional Variation and Importance of Blood Cells

Open access
Erickson, Michelle A., Morofuji, Yoichi, Owen, Joshua B., Banks, William A.·2014·The Journal of Pharmacology and Experimental Therapeutics

Abstract

Increased blood levels of the eotaxin chemokine C-C motif ligand 11 (CCL11) in aging were recently shown to negatively regulate adult hippocampal neurogenesis. How circulating CCL11 could affect the central nervous system (CNS) is not clear, but one possibility is that it can cross the blood-brain barrier (BBB). Here, we show that CCL11 undergoes bidirectional transport across the BBB. Transport of CCL11 from blood into whole brain (influx) showed biphasic kinetics, with a slow phase preceding a rapid phase of uptake. We found that the slow phase was explained by binding of CCL11 to cellular components in blood, whereas the rapid uptake phase was mediated by direct interactions with the BBB. CCL11, even at high doses, did not cause BBB disruption. All brain regions except striatum showed a delayed rapid-uptake phase. Striatum had only an early rapid-uptake phase, which was the fastest of any brain region. We also observed a slow but saturable transport system for CCL11 from brain to blood. C-C motif ligand 3 (CCR3), an important receptor for CCL11, did not facilitate CCL11 transport across the BBB, although high concentrations of a CCR3 inhibitor increased brain uptake without causing BBB disruption. Our results indicate that CCL11 in the circulation can access many regions of the brain outside of the neurogenic niche via transport across the BBB. This suggests that blood-borne CCL11 may have important physiologic functions in the CNS and implicates the BBB as an important regulator of physiologic versus pathologic effects of this chemokine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1124/jpet.114.213074

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CCL11 efficiently crosses the blood brain barrier, has been implicated in neuroinflammatory disorders and SARS-CoV-2 cognitive impairment, and impairs neurogenesis.

    “CCL11 efficiently crosses the blood brain barrier56, has been implicated in neuroinflammatory disorders and SARS-CoV-2 (COVID-19) cognitive impairment57,58, and impairs neurogenesis54,58,59.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Jorm AF (2000) Is depression a risk factor for dementia or cognitive decline? A review. Gerontology 46:219-227.

Cited by

Sorted by citations

Authors
Erickson, M. A., Morofuji, Y., Owen, J. B., & Banks, W. A.
Affiliations
University of Nagasaki (JP)
Venue
The Journal of Pharmacology and Experimental Therapeutics
Publisher
Elsevier BV
Published
2014-06
Volume
349
Issue
3
Pages
497-507
ISSN
0022-3565 (ISSN-L)
OpenAlex
W2168315986
Cited by
110
References
4
Citations by year
2026: 5 · 2025: 19 · 2024: 10 · 2023: 7 · 2022: 9 · 2021: 10 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 10 · 2016: 11 · 2015: 4 · 2014: 1
FWCI
4.51
Type
journal article
Language
en
Open access
Locations
  • Journal of Pharmacology and Experimental Therapeutics (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (AG029839)
  • National Institute on Aging (R01AG029839)
  • National Institute of Neurological Disorders and Stroke (R01NS051334)
  • National Institute of Environmental Health Sciences (T32ES019851, P30ES013508)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
Keywords
eotaxin, blood-brain barrier, bidirectional transport, striatum, CCR3, hippocampal neurogenesis, aging, blood-brain barrier disruption
MeSH terms
Animals, Biological Transport, Blood-Brain Barrier, Brain, Cells, Cultured, Enzyme-Linked Immunosorbent Assay, Injections, Intravenous, Iodine Radioisotopes, Male, Regression Analysis, Tissue Distribution, Endothelial Cells, Mice, Chemokine CCL11, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review